<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040685</url>
  </required_header>
  <id_info>
    <org_study_id>PR139/21</org_study_id>
    <nct_id>NCT05040685</nct_id>
  </id_info>
  <brief_title>Axillary Reverse Mapping in Breast Cancer</brief_title>
  <acronym>ARM</acronym>
  <official_title>Axillary Reverse Mapping (ARM): Validation of Surgical Tecnique in Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The axillary mapping reverse (ARM) consists in differentiating the upper limb lymph nodes&#xD;
      from the breast ones in order to preserve them and reduce the possibility of lymphedema.&#xD;
&#xD;
      A significant decrease of lymphedema rates in patients who was possible associate ARM&#xD;
      technique during the axillary surgery improving the quality of life of these patients. There&#xD;
      are different visualisation techniques like fluorescence dye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Axillary lymph node dissection (ALND) was the standard therapy until 1990-2000, when the&#xD;
      technique was replaced, when possible, by another procedure associated with less morbidity:&#xD;
      the sentinel lymph node biopsy (SLNB). However, actually, ALND is still the gold standard in&#xD;
      some patients. This procedure is associated with substantial morbidity, like lymphedema,&#xD;
      shoulder pain, arm numbness, axillary web syndrome and decreased upper-extremity range of&#xD;
      motion (ROM), that severely conditions the quality of life of these patients.&#xD;
&#xD;
      In 2007, the investigators had the first reports about a new surgical technique, the axillary&#xD;
      mapping reverse (ARM), that consists in differentiating the upper limb lymph nodes from the&#xD;
      breast ones in order to preserve them and reduce the possibility of lymphedema.&#xD;
&#xD;
      The current literature shows a significant decrease of lymphedema rates in patients who was&#xD;
      possible associate this technique during the axillary surgery improving the quality of life&#xD;
      of these patients. There are different visualisation techniques. With the use of indocyanine&#xD;
      green, the visualisation rates in the axilla of ARM lymphatics are from 88%, similar to other&#xD;
      techniques. Some advantages of fluorescence dye are that no systemic allergic reactions have&#xD;
      been reported and the 'green tattoo' disappears quickly.&#xD;
&#xD;
      HYPHOTESIS The axillary mapping reverse (AMR) is able to identify the lymph nodes responsible&#xD;
      for lymphatic drainage of the ipsilateral upper limb (ARM nodes) in breast cancer patients&#xD;
      who underwent an axillar lymph node dissection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective not randomized pilot study to validate the axillary mapping reverse technique by using indocyanine green.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who it is possible preserve ARM nodes</measure>
    <time_frame>1 year</time_frame>
    <description>Determinate the percentage of patients who is possible preserve the ARM node during ALND</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of metastatic ARM</measure>
    <time_frame>1 year</time_frame>
    <description>Determinate the percentage of metastatic ARM nodes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymph Node Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Axillary mapping reverse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of axillary mapping reverse technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary mapping reverse</intervention_name>
    <description>At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.</description>
    <arm_group_label>Axillary mapping reverse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who will undergo ALND in the treatment of breast cancer:&#xD;
&#xD;
          -  cT4a, cT4c and cT4d.&#xD;
&#xD;
          -  cT4b with extensive involvement of the skin.&#xD;
&#xD;
          -  cN0 with SLNB positive (pN+) that need to associate ALND:&#xD;
&#xD;
               -  cT3-T4b.&#xD;
&#xD;
               -  &gt;2 lymph node macrometastasis if cTis, cT1 and cT2.&#xD;
&#xD;
               -  Patients who underwent mastectomy and it is not possible associate adjuvant&#xD;
                  radiotherapy.&#xD;
&#xD;
          -  cN1:&#xD;
&#xD;
               -  If primary surgery treatment.&#xD;
&#xD;
               -  After neoadjuvant systemic treatment, if there is not a clinical-radiological&#xD;
                  complete response and/or SLNB positive (ypN+).&#xD;
&#xD;
          -  cN2:&#xD;
&#xD;
               -  If primary surgery treatment.&#xD;
&#xD;
               -  After neoadjuvant systemic treatment, if luminal tumours or there is not a&#xD;
                  clinical-radiological complete response in triple negative or HER2 overexpressed&#xD;
                  tumours.&#xD;
&#xD;
          -  cN3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous axillary surgery (except sentinel node biopsy)&#xD;
&#xD;
          -  Patients who did previous axillary radiotherapy treatment.&#xD;
&#xD;
          -  Patients who do not wish to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Ortega Expósito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
    <phone>932607500</phone>
    <phone_ext>2814</phone_ext>
    <email>agaciat@bellvitgehospital.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Ortega Expósito, MD</last_name>
    <phone>932607500</phone>
    <phone_ext>2814</phone_ext>
    <email>cortegae@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
      <phone>0034-660223417</phone>
      <email>agarciat@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Amparo Garcia-Tejedor</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphedema</keyword>
  <keyword>Sentinel lymph node</keyword>
  <keyword>Axillary lymph node dissection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

